AISAP, an Israeli medical startup pioneering AI-driven diagnostics, has been recognized as one of the world’s most innovative and promising companies for 2025 by Fast Company. The company secured fourth place globally in the healthcare category, a remarkable achievement that underscores the international recognition of its groundbreaking technology and its impact on the future of medicine.
AISAP was founded by Adiel Am-Shalom, a former officer in Israel’s elite 8200 intelligence unit, alongside leading medical professionals: Professor Ehud Raanani, Professor Robert Klempner, and Professor Ehud Schwammenthal. The company has raised approximately $13 million in funding from investors including Harel Insurance, Shoni Health, and former Mossad director Tamir Pardo.
AISAP has developed AISAP CARDIO, the world’s first real-time AI-powered cardiac diagnostic platform. This technology enables life-saving bedside diagnostics, allowing for immediate and highly accurate detection of structural heart diseases and heart failure. The platform recently received FDA approval, marking a historic milestone in AI-driven medical diagnostics.
“The recognition by Fast Company is a source of immense pride for us as Israelis and highlights the global relevance of the problem we are solving,” said Adiel Am-Shalom, AISAP’s co-founder and CEO, in a statement. “This is a strong validation that our product can influence the future of medicine worldwide and save countless lives through real-time, precise diagnostics.”
Professor Ehud Raanani, co-founder and board member, emphasized the significance of their achievement, stating: “We are proud to be the first company to secure FDA approval under the unique CADx pathway for comprehensive AI-based diagnostics at the point of care. We remain committed to driving innovation and improving the lives of millions of patients worldwide.”
Keep reading at jpost.com.
AISAP Co-founder Ehud Raanani is a Technion alumnus.
